Investigation of CD40 -1C>T Genetic Variant and sCD40 Levels in Colorectal Cancer
Yıl: 2022 Cilt: 11 Sayı: 2 Sayfa Aralığı: 67 - 73 Metin Dili: İngilizce DOI: 10.5505/ktd.2022.62343 İndeks Tarihi: 09-10-2022
Investigation of CD40 -1C>T Genetic Variant and sCD40 Levels in Colorectal Cancer
Öz: Introduction: Functional studies have shown that cancer cells inactivate CD40-CD40L costimulators, which contribute to immune escape by inhibiting CD40L expression. CD40 -1C>T (rs1883832) is a 5′ UTR variant and may cause changes in protein level or function in the posttranslational process. In this article, we aimed to determine the importance of CD40 - 1C>T variant in terms of histopathological criteria and its effect on sCD40 levels in patients with CRC (colorectal cancer). Methods: In peripheral blood samples of ninety-three CRC and one hundred sixty-three controls, sCD40 level was detected by ELISA, and CD40-1C>T variant was detected by PCR-RFLP. Results: 1.48 times higher sCD40 level was found in CRC with CT compared to those with CC (p=0.007). The frequency of CT and TT genotypes was found to be higher in early tumor stage than in advanced tumor stage (p=0.041). It was observed that the frequency of CT genotype was higher in patients with distant organ metastases compared to those without. (p=0.02). Dsicussion and Conclusion: We do not think that the CD40-1C>T variant is an important part of CRC initiation. On the other hand, our findings in favor of metastasis suggest that CD40 is a factor that may be effective in the progression stages.
Anahtar Kelime: CD40 -1C>T Genetik Varyantı ve sCD40 Düzeylerinin Kolorektal Kanserde İncelenmesi
Öz: Giriş ve Amaç: Fonksiyonel çalışmalar, kanser hücrelerinin CD40L ekspresyonunu inhibe ederek immün kaçışa katkıda bulunan CD40- CD40L kostimülatörlerini etkisiz hale getirdiğini göstermiştir. CD40 -1C>T (rs1883832) bir 5′ UTR varyantıdır ve translasyon sonrası süreçte protein düzeyinde veya işlevinde değişikliklere neden olabilir. Bu yazıda, KRK (kolorektal kanser) hastalarında CD40 -1C>T varyantının histopatolojik kriterler açısından önemini ve sCD40 düzeylerine etkisini belirlemeyi amaçladık. Yöntem ve Gereçler: Doksan üç KRK ve Yüz altmış üç kontrole ait periferik kan örneklerinde ELISA ile sCD40 düzeyi ve PCR-RFLP ile CD40-1C>T varyantı saptandı. Bulgular: KRK’de CT genotipi taşıyanlarda CC’ye göre 1.48 kat daha yüksek sCD40 seviyesi bulundu (p=0.007). CT ve TT genotiplerinin sıklığı, erken tümör evresinde, ileri evre tümör evresine göre daha yüksek olarak saptandı (p=0.041). CT genotipi sıklığı uzak organ metastazı taşıyanlarda taşımayanlara göre yüksek olduğu izlendi (p=0.02). Tartışma ve Sonuç: CD40-1C>T varyantının CRC başlatmanın önemli bir parçası olduğunu düşünmüyoruz. Öte yandan metastaz lehine bulgularımız CD40’ın progresyon evrelerinde etkili olabilecek bir faktör olduğunu düşündürmektedir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Laman JD, Claassen E, Noelle RJ. Functions of CD40 and Its Ligand, gp39 (CD40L). Crit Rev Immunol. 2017; 37(2- 6): 371-420.
- Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y and Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009; 229(1): 152- 72.
- Fanslow WC, Srinivasan S, Paxton R, Gibson MG, Spriggs MK and Armitage RJ. Structural characteristics of CD40 ligand that determine biological function. Semin Immunol. 1994; 6(5): 267-78.
- Stamenkovic I, Clark EA, Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. Embo J. 1989; 8: 1403– 10.
- Ma Y, Shurin GV, Peiyuan Z, Shurin MR. Dendritic cells in the cancer microenvironment. J Cancer. 2013; 4(1): 36-44.
- Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007; 25(7): 876-83.
- Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R, et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 2010; 95(5): 845-8.
- Zhou G, Wang Y, Fang Z, Liu R, Wang A, Zhao F, et al. CD40 -1C>T polymorphism and the risk of lung cancer in a Chinese population. Int J Clin Exp Pathol. 2015; 8(11): 15163-9.
- Nieters A, Bracci PM, de Sanjosé S, Becker N, Maynadié M, Benavente Y, et al. A functional TNFRSF5 polymorphism and risk of non-Hodgkin lymphoma, a pooled analysis. Int J Cancer. 2011 ;128(6): 1481-5
- Krishnappa P, Kong HM, Mohamad IB, Voon K, Somanath SD. CD40 polymorphism in cervical carcinoma in a subset of Malaysian population. J Obstet Gynaecol Res. 2017; 43(5): 923-928.
- Shuang C, Dalin L, Weiguang Y, Zhenkun F, Fengyan X, Da P, et al. Association of CD40 gene polymorphisms with sporadic breast cancer in Chinese Han women of Northeast China. PLoS One. 2011; 6(8): e23762.
- Dolen Y, Yilmaz G, Esendagli G, Guler NE, Guc D. CD40 -1C>T single nucleotide polymorphism and CD40 expression on breast tumors. Cytokine. 2010; 50(3): 243-4.
- Dimitrakopoulos FD, Antonacopoulou AG, Kottorou AE, Kalofonou M, Panagopoulos N, Dougenis D, et al. Genetic Variations of CD40 and LTβR Genes Are Associated With Increased Susceptibility and Clinical Outcome of Non-Small-Cell Carcinoma Patients. Front Oncol. 2021; 11: 721577.
- Castro JE, Melo-Cardenas J, Urquiza M, Barajas-Gamboa JS, Pakbaz RS, Kipps TJ. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res. 2012; 72(12): 2937-48.
- Wierda WG, Castro JE, Aguillon R, Sampath D, Jalayer A, McMannis J, Prussak CE, et al. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia. 2010; 24(11):1893-900.
- Skibola CF, Nieters A, Bracci PM, Curry JD, Agana L, Skibola DR, et al. A functional TNFRSF5 gene variant is associated with risk of lymphoma. Blood. 2008; 111(8): 4348-54.
- Deskur A, Sałata D, Budkowska M, Dołęgowska B, Starzyńska T, Błogowski W. Selected hemostatic parameters in patients with pancreatic tumors. Am J Transl Res. 2014; 6(6): 768-76.
- Mu CY, Qin PX, Qu QX, Chen C, Huang JA. Soluble CD40 in plasma and malignant pleural effusion with non-small cell lung cancer: A potential marker of prognosis. Chronic Dis Transl Med. 2015; 1(1): 36-41.
- Mielczarek-Palacz A, Sikora J, Kondera Anasz Z, Hauza G. Imbalance in serum soluble CD30/CD30L and CD40/CD40L systems are associated with ovarian tumors. Hum Immunol. 2013; 74(1): 70-4.
- Hock BD, McKenzie JL, Patton NW, Drayson M, Taylor K, Wakeman C, et al. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer. 2006; 106(10): 2148-57.
- Pang X, Zhang L, Wu J, Ma C, Mu C, Zhang G, Chen W. Expression of CD40/CD40L in colon cancer, and its effect on proliferation and apoptosis of SW48 colon cancer cells. J BUON. 2017; 22(4): 894-899.
- Meltzer S, Torgunrud A, Abrahamsson H, Solbakken AM, Flatmark K, Dueland S, et al. The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer. Br J Cancer. 2021; 125(2): 240- 246.
| APA | Horozoğlu C, KARADAĞ H, SÖNMEZ D, HAKAN M, KÜÇÜKHÜSEYİN Ö, Yılmaz Ü, Yaylim I, DEMİRKOL Ş, arıkan s (2022). Investigation of CD40 -1C>T Genetic Variant and sCD40 Levels in Colorectal Cancer. , 67 - 73. 10.5505/ktd.2022.62343 |
| Chicago | Horozoğlu Cem,KARADAĞ Hazal,SÖNMEZ Dilara,HAKAN Mehmet Tolgahan,KÜÇÜKHÜSEYİN Özlem,Yılmaz Ümit,Yaylim Ilhan,DEMİRKOL ŞEYDA,arıkan soykan Investigation of CD40 -1C>T Genetic Variant and sCD40 Levels in Colorectal Cancer. (2022): 67 - 73. 10.5505/ktd.2022.62343 |
| MLA | Horozoğlu Cem,KARADAĞ Hazal,SÖNMEZ Dilara,HAKAN Mehmet Tolgahan,KÜÇÜKHÜSEYİN Özlem,Yılmaz Ümit,Yaylim Ilhan,DEMİRKOL ŞEYDA,arıkan soykan Investigation of CD40 -1C>T Genetic Variant and sCD40 Levels in Colorectal Cancer. , 2022, ss.67 - 73. 10.5505/ktd.2022.62343 |
| AMA | Horozoğlu C,KARADAĞ H,SÖNMEZ D,HAKAN M,KÜÇÜKHÜSEYİN Ö,Yılmaz Ü,Yaylim I,DEMİRKOL Ş,arıkan s Investigation of CD40 -1C>T Genetic Variant and sCD40 Levels in Colorectal Cancer. . 2022; 67 - 73. 10.5505/ktd.2022.62343 |
| Vancouver | Horozoğlu C,KARADAĞ H,SÖNMEZ D,HAKAN M,KÜÇÜKHÜSEYİN Ö,Yılmaz Ü,Yaylim I,DEMİRKOL Ş,arıkan s Investigation of CD40 -1C>T Genetic Variant and sCD40 Levels in Colorectal Cancer. . 2022; 67 - 73. 10.5505/ktd.2022.62343 |
| IEEE | Horozoğlu C,KARADAĞ H,SÖNMEZ D,HAKAN M,KÜÇÜKHÜSEYİN Ö,Yılmaz Ü,Yaylim I,DEMİRKOL Ş,arıkan s "Investigation of CD40 -1C>T Genetic Variant and sCD40 Levels in Colorectal Cancer." , ss.67 - 73, 2022. 10.5505/ktd.2022.62343 |
| ISNAD | Horozoğlu, Cem vd. "Investigation of CD40 -1C>T Genetic Variant and sCD40 Levels in Colorectal Cancer". (2022), 67-73. https://doi.org/10.5505/ktd.2022.62343 |
| APA | Horozoğlu C, KARADAĞ H, SÖNMEZ D, HAKAN M, KÜÇÜKHÜSEYİN Ö, Yılmaz Ü, Yaylim I, DEMİRKOL Ş, arıkan s (2022). Investigation of CD40 -1C>T Genetic Variant and sCD40 Levels in Colorectal Cancer. Kocaeli Tıp Dergisi, 11(2), 67 - 73. 10.5505/ktd.2022.62343 |
| Chicago | Horozoğlu Cem,KARADAĞ Hazal,SÖNMEZ Dilara,HAKAN Mehmet Tolgahan,KÜÇÜKHÜSEYİN Özlem,Yılmaz Ümit,Yaylim Ilhan,DEMİRKOL ŞEYDA,arıkan soykan Investigation of CD40 -1C>T Genetic Variant and sCD40 Levels in Colorectal Cancer. Kocaeli Tıp Dergisi 11, no.2 (2022): 67 - 73. 10.5505/ktd.2022.62343 |
| MLA | Horozoğlu Cem,KARADAĞ Hazal,SÖNMEZ Dilara,HAKAN Mehmet Tolgahan,KÜÇÜKHÜSEYİN Özlem,Yılmaz Ümit,Yaylim Ilhan,DEMİRKOL ŞEYDA,arıkan soykan Investigation of CD40 -1C>T Genetic Variant and sCD40 Levels in Colorectal Cancer. Kocaeli Tıp Dergisi, vol.11, no.2, 2022, ss.67 - 73. 10.5505/ktd.2022.62343 |
| AMA | Horozoğlu C,KARADAĞ H,SÖNMEZ D,HAKAN M,KÜÇÜKHÜSEYİN Ö,Yılmaz Ü,Yaylim I,DEMİRKOL Ş,arıkan s Investigation of CD40 -1C>T Genetic Variant and sCD40 Levels in Colorectal Cancer. Kocaeli Tıp Dergisi. 2022; 11(2): 67 - 73. 10.5505/ktd.2022.62343 |
| Vancouver | Horozoğlu C,KARADAĞ H,SÖNMEZ D,HAKAN M,KÜÇÜKHÜSEYİN Ö,Yılmaz Ü,Yaylim I,DEMİRKOL Ş,arıkan s Investigation of CD40 -1C>T Genetic Variant and sCD40 Levels in Colorectal Cancer. Kocaeli Tıp Dergisi. 2022; 11(2): 67 - 73. 10.5505/ktd.2022.62343 |
| IEEE | Horozoğlu C,KARADAĞ H,SÖNMEZ D,HAKAN M,KÜÇÜKHÜSEYİN Ö,Yılmaz Ü,Yaylim I,DEMİRKOL Ş,arıkan s "Investigation of CD40 -1C>T Genetic Variant and sCD40 Levels in Colorectal Cancer." Kocaeli Tıp Dergisi, 11, ss.67 - 73, 2022. 10.5505/ktd.2022.62343 |
| ISNAD | Horozoğlu, Cem vd. "Investigation of CD40 -1C>T Genetic Variant and sCD40 Levels in Colorectal Cancer". Kocaeli Tıp Dergisi 11/2 (2022), 67-73. https://doi.org/10.5505/ktd.2022.62343 |
